The clinical safety and efficacy of low dose rituximab regimen on patients with Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation

VernacularTitle: 小剂量利妥昔单抗治疗异基因造血干细胞移植后EB病毒感染相关性疾病的疗效及安全性观察
Author: Hao AI ¹ ; Yuewen FU ; Qian WANG ; Xingchen LIU ; Xudong WEI ; Yongping SONG
Author Information

1. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
Publication Type:Case Reports
Keywords: Epstein-Barr virus; Allogeneic haematopoietic stem cell transplantation; Rituximab
From: Chinese Journal of Internal Medicine 2018;57(8):592-595
CountryChina
Language:Chinese
Abstract: To retrospectively analyze the safety and efficacy of low dose rituximab regimen in patients with Epstein-Barr virus (EBV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Among 12 cases, 11 achieved complete remission (CR), 1 with partial remission (PR). Patients received 15 infusions with a median of 2.5(1-4) in each. The EBV DNA negative transformation period was 5-25 days with median 12 days. Low dose rituximab could be an alternative choice in patients with EBV infection after allo-HSCT.